Sage Therapeutics appoints Laura M. Gault as CMO

Sage Therapeutics, a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Laura Gault, MD, Ph.D. as Chief Medical Officer. In her new role, Dr. Gault will focus on advancing Sage’s current and emerging product pipeline through all stages of development.

“We are thrilled to have Dr. Gault join Sage to lead the development and delivery of our pipeline of potential new medicines and be a partner in our mission to improve the lives of people affected by brain health disorders,” said Barry Greene, Chief Executive Officer at Sage Therapeutics. “Dr. Gault’s vision, experience and deep commitment to this field of medicine complements our tremendous sense of urgency to create novel medicines for people who currently lack adequate treatment options.”

Dr. Gault brings more than 15 years of pharmaceutical industry experience advancing programs at early and late stages of development in rare and common diseases. She has led multidisciplinary teams focusing in neuropsychiatry, neuroinflammation and neurodegeneration and has extensive knowledge of clinical trial design and conduct, and the regulatory landscape in these areas. In her previous role, Dr. Gault was Vice President, Therapeutic Area Head for Neurology and Ophthalmology at Alexion/Astra Zeneca Rare Disease and was responsible for the development of ravulizumab in generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) and the initiation of new programs in dermatomyositis, Guillain-Barré syndrome, geographic atrophy and gMG. Prior to that, she held positions as Vice President, Neurology Clinic Development at Vertex Pharmaceuticals and Group Project Leader at AbbVie.

Dr. Gault received an M.D. and a Ph.D. in Neuroscience from Case Western Reserve University and a B.S. in Behavioral Neuroscience from the University of Pittsburgh. She completed an internship in Pediatrics, followed by residency in Adult Psychiatry and fellowship in Child and Adolescent Psychiatry at Yale University.

“Sage is leading the way in addressing brain health with purposeful science and a dedicated focus on what matters most to patients. I’m excited to join this team at a time of incredible momentum, as the company advances toward important milestones in its work to evolve the treatment landscape in depression, neurology, and neuropsychiatry,” said Dr. Gault. “The time to change how we treat these complex and debilitating disorders is now, and I look forward to working with my colleagues at Sage to drive this change.” Business Wire